Compare · ABBV vs LPTX
ABBV vs LPTX
Side-by-side comparison of AbbVie Inc. (ABBV) and Leap Therapeutics Inc. (LPTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and LPTX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV carries a market cap of $520.65B.
- ABBV has hit the wire 15 times in the past 4 weeks while LPTX has been quiet.
- ABBV has more recent analyst coverage (25 ratings vs 5 for LPTX).
- Company
- AbbVie Inc.
- Leap Therapeutics Inc.
- Price
- -
- -
- Market cap
- $520.65B
- -
- 1M return
- +3.18%
- -
- 1Y return
- +25.96%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- News (4w)
- 15
- 0
- Recent ratings
- 25
- 5
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Leap Therapeutics Inc.
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 that is in multiple clinical trials for treating esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, and prostate cancer. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Latest ABBV
- EVP, CHIEF COMMERCIAL OFFICER Stewart Jeffrey Ryan exercised 40,619 shares at a strike of $101.75, sold $11,925,738 worth of shares (40,619 units at $293.60) and gifted 3,450 shares, decreasing direct ownership by 4% to 79,721 units (SEC Form 4)
- Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medications
- SEC Form 10-Q filed by AbbVie Inc.
- Allergan Aesthetics to Present New Research on Aesthetic Care Following Medical Weight Loss and Evolving Patient Needs at ASDS 2026
- AbbVie Inc. filed SEC Form 8-K: Leadership Update
- Brise Pharmaceuticals Announces Global License Agreement with AbbVie to Advance the Next-Generation of Migraine Therapies
- AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AbbVie Reports Third-Quarter 2026 Financial Results
- AbbVie TEMPLE Study Demonstrates Superior Tolerability and Efficacy of Atogepant (QULIPTA®) in Head-to-Head Migraine Prevention Trial
- The Countdown Is On: BOTOX® Cosmetic (onabotulinumtoxinA) Day is Back Nov. 18
Latest LPTX
- SEC Form 4 filed by CEO,CFO,Pres.,GC,Treas.&Sec. Onsi Douglas E
- SEC Form 4 filed by Director Li William
- SEC Form 4 filed by Director Richard Christian M
- SEC Form 4 filed by Director Mashiach Nissim
- SEC Form 4 filed by Director Martin Patricia A.
- SEC Form 4 filed by Director Schilsky Richard
- SEC Form 4 filed by Director Loscalzo Joseph
- SEC Form 4 filed by Director Cavanaugh James H
- SEC Form 4 filed by Director Mirabelli Christopher
- SEC Form 4 filed by Director Dietz Thomas John